- ICD-10-CM Codes ›
- C00-D49 ›
- C7B-C7B ›
- C7B- ›
- 2024 ICD-10-CM Diagnosis Code C7B
Secondary neuroendocrine tumors
- 2016 2017 2018 2019 2020 2021 2022 2023 2024 Non-Billable/Non-Specific Code
- C7B should not be used for reimbursem*nt purposes as there are multiple codes below it that contain a greater level of detail.
- The 2024 edition of ICD-10-CM C7B became effective on October 1, 2023.
- This is the American ICD-10-CM version of C7B - other international versions of ICD-10 C7B may differ.
Use Additional
Use Additional Help
Certain conditions have both an underlying etiology and multiple body system manifestations due to the underlying etiology. For such conditions the ICD-10-CM has a coding convention that requires the underlying condition be sequenced first followed by the manifestation. Wherever such a combination exists there is a "use additional code" note at the etiology code, and a "code first" note at the manifestation code. These instructional notes indicate the proper sequencing order of the codes, etiology followed by manifestation. In most cases the manifestation codes will have in the code title, "in diseases classified elsewhere." Codes with this title are a component of the etiology/manifestation convention. The code title indicates that it is a manifestation code. "In diseases classified elsewhere" codes are never permitted to be used as first listed or principle diagnosis codes. They must be used in conjunction with an underlying condition code and they must be listed following the underlying condition.
- code to identify any functional activity
The following code(s) above C7B contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
- Applicable To annotations, or
- Code Also annotations, or
- Code First annotations, or
- Excludes1 annotations, or
- Excludes2 annotations, or
- Includes annotations, or
- Note annotations, or
- Use Additional annotations
that may be applicable to C7B:
- C00-D49
2024 ICD-10-CM Range C00-D49
NeoplasmsNeoplasms
Note
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
Code History
- 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
- 2017 (effective 10/1/2016): No change
- 2018 (effective 10/1/2017): No change
- 2019 (effective 10/1/2018): No change
- 2020 (effective 10/1/2019): No change
- 2021 (effective 10/1/2020): No change
- 2022 (effective 10/1/2021): No change
- 2023 (effective 10/1/2022): No change
- 2024 (effective 10/1/2023): No change
Code annotations containing back-references to C7B:
- Type 1 Excludes: C79, C79
ICD-10-CM Diagnosis Code C79
Secondary malignant neoplasm of other and unspecified sites
- 2016 2017 2018 2019 2020 2021 2022 2023 2024 Non-Billable/Non-Specific Code
Type 1 Excludes
- secondary carcinoid tumors (C7B.-)
- secondary neuroendocrine tumors (C7B.-)
ICD-10-CM Diagnosis Code C79
Secondary malignant neoplasm of other and unspecified sites
- 2016 2017 2018 2019 2020 2021 2022 2023 2024 Non-Billable/Non-Specific Code
Type 1 Excludes
- secondary carcinoid tumors (C7B.-)
- secondary neuroendocrine tumors (C7B.-)
ICD-10-CM Codes Adjacent To C7B
C7A.090 Malignant carcinoid tumor of the bronchus and lung
C7A.091 Malignant carcinoid tumor of the thymus
C7A.092 Malignant carcinoid tumor of the stomach
C7A.093 Malignant carcinoid tumor of the kidney
C7A.094 Malignant carcinoid tumor of the foregut, unspecified
C7A.095 Malignant carcinoid tumor of the midgut, unspecified
C7A.096 Malignant carcinoid tumor of the hindgut, unspecified
C7A.098 Malignant carcinoid tumors of other sites
C7A.1 Malignant poorly differentiated neuroendocrine tumors
C7A.8 Other malignant neuroendocrine tumors
C7B Secondary neuroendocrine tumors
C7B.0 Secondary carcinoid tumors
C7B.00 …… unspecified site
C7B.01 …… of distant lymph nodes
C7B.02 …… of liver
C7B.03 …… of bone
C7B.04 …… of peritoneum
C7B.09 …… of other sites
C7B.1 Secondary Merkel cell carcinoma
C7B.8 Other secondary neuroendocrine tumors
C76 Malignant neoplasm of other and ill-defined sites
Reimbursem*nt claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.